PP
NAUT icon

PDS Planning’s Nautilus Biotechnolgy NAUT Stock Holding History

PDS Planning’s Portfolio NAUT Stock Details NAUT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-10,455
Closed -$33K – 375
2023
Q3 		$33K Hold
10,455
– – ﹤0.01% 337
2023
Q2 		$40.5K Buy
+10,455
New +$30.1K 0.01% 339

Other funds holding NAUT

ACM
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
CM
Cercano Management Bellevue, Washington $750M AUM 25.77% 1-Year Est. Return
MVG
Madrona Venture Group Seattle, Washington $22.1M AUM 86.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CFM
Comprehensive Financial Management Los Gatos, California $3.05B AUM 1.77% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
ACI
Amazon.com Inc Seattle, Washington $4.42B AUM 22.6% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PDS Planning's NAUT Position: Q4 2023 in Review

PDS Planning sold out of Nautilus Biotechnolgy (NAUT) in Q4 2023, closing a stake of 10,455 shares — an estimated $33K sold.

PDS Planning first reported a position in NAUT in Q2 2023 and held it in 2 quarters. The position peaked at $40.5K in Q2 2023. 76 funds tracked by Wall St. Rank hold NAUT as of Q4 2023.

  • PDS Planning reported no remaining Nautilus Biotechnolgy position as of Q4 2023 after selling out during the quarter.
  • PDS Planning sold 10,455 Nautilus Biotechnolgy shares in Q4 2023, an estimated $33K.
  • PDS Planning first reported a position in Nautilus Biotechnolgy in Q2 2023 and held it in 2 quarters.
  • PDS Planning's Nautilus Biotechnolgy position peaked at $40.5K in Q2 2023.
  • 76 funds tracked by Wall St. Rank held Nautilus Biotechnolgy as of Q4 2023.

Based on PDS Planning's 13F filing for Q4 2023, filed 1 Feb 2024.